PDOs with high HHLA2 expression showed significantly greater cell death and cytotoxicity in response to the c-Met inhibitor PHA665752 compared to those with low HHLA2 expression (Fig. 6D-F, Supplemental Fig. 12F), suggesting HHLA2 can predict response to c-Met inhibitors in HCC. The gene discussed is HHLA2; the disease is hepatocellular carcinoma.